Virpax Pharmaceuticals, Inc. · OTC:VRPX

Virpax Pharmaceuticals — IPO Roadshow (September 2021)

31 slides from Virpax Pharmaceuticals's IPO roadshow presentation, Sep 10, 2021

  1. Slide 1: Optimizing Delivery of Non-Addictive Pain Medicines

    OPTIMIZING DELIVERY OF NON - ADDICTIVE PAIN MEDICINES SEPTEMBER 2021 Investor Presentation BUPIVACAINE Injectable Hydrogel for the extended release of local anesthetic DICLOFENAC Spray Film A topical anti - inflammatory for localized musculoskeletal pain ( Image is for illustration purposes only) EN

  2. Slide 2: Cautionary Note on Forward Looking Statements and Disclaimers

    CAUTIONARY NOTE ON FORWARD LOOKING STATEMENTS AND DISCLAIMERS All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, a

  3. Slide 3: Mission Statement

    MISSION STATEMENT Our mission is to improve widely - used and newly - developed non - addictive pain medicines, as well as neurological product candidates, by optimizing our proprietary delivery systems. 3 NASDAQ:VRPX

  4. Slide 4: Investment Highlights

    INVESTMENT HIGHLIGHTS 4 ▪ Addressing an unmet global need in pain management with non - addictive, non - opioid pain product candidates ▪ 20% of the US population suffers from chronic pain 1 ▪ 3X INCREASE in opioid prescriptions in the last 20 years 2 ▪ Attempting to enhance the effectiveness of app

  5. Slide 5: Franchise Pipeline

    5 NASDAQ:VRPX FRANCHISE PIPELINE

  6. Slide 6: Virpax Therapies' Drug Delivery Systems

    VIRPAX THERAPIES’ DRUG DELIVERY SYSTEMS THE IMPORTANT ROLE OF DRUG DELIVERY AND THE BENEFITS OF PROPRIETARY FORMULATIONS 6 NASDAQ:VRPX DELIVERY Facilitated drug delivery by transport along the olfactory neurons NOSE ACUTE AND CHRONIC PAIN, INCLUDING CANCER PAIN CONCEPT Multi - use device and pressur

  7. Slide 7: Non-Addictive Analgesics Formulations in Development

    NON - ADDICTIVE ANALGESICS FORMULATIONS IN DEVELOPMENT DRUG TYPE NSAID topical spray film INDICATION Localized Musculoskeletal Pain ADDRESSABLE US MARKET $3.3 Billion Topical musculoskeletal pain market (2019) CURRENT DRUG DELIVERY LIMITATIONS ▪ Low permeability of topical creams ▪ Poor patch adhesi

  8. Slide 8: Recent Events

    RECENT EVENTS 8 ▪ IND Enabling Studies of Envelta ҹ underway in partnership with the NIH ▪ Charles River Laboratories initiated preclinical IND enabling studies of Epoladerm ҹ as of August 24, 2021 ▪ Entered into a commercial manufacturing and clinical supply agreement with Seqens for AnQlar ҹ (MMS0

  9. Slide 9: Envelta Regulatory Pathway and Market Size

    INDICATION REGULATORY PATHWAY FDA PRE - IND GUIDANCE PHASE 1 PHASE 2 PHASE 3 NDA SUBMISSION Acute and Chronic Pain, including Pain associated with Cancer INDICATION MARKET SIZE DELIVERY SYSTEM Intranasal Enkephalin For Acute and Chronic Pain, including Pain associated with Cancer $ 7.0 BILLION NCE E

  10. Slide 10: The Novel Role of Enkephalins in Pain Management

    ▪ Enkephalins are naturally occurring analgesics in our body Enkephalins have limited therapeutic potential as they are quickly metabolized and unable to cross the blood−brain barrier (BBB) to reach their target receptors Enkephalins bind predominantly to the delta - receptor which is typically not

  11. Slide 11: Envelta Delivers Enkephalin Nanoparticles with MET

    ENVELTA ҹ DELIVERS ENKEPHALIN NANOPARTICLES WITH MOLECULAR ENVELOPE TECHNOLOGY (MET) TECHNOLOGY & IP ▪ Leucine Enkephalin (L - ENK) nanoparticles in powdered form delivered through a novel intranasal device ▪ Expiry: 11/03/34 MARKET OPPORTUNITY ▪ Potentially disrupt opioid analgesic market for the t

  12. Slide 12: Envelta Proprietary Delivery Device

    CONCEPT Single patient, multi - use device Single - use cartridges Easy activation CARTRIDGE Sealed in inert gas Pressurized Defined release ▪ No breath coordination required, simply hold the device to the nostril and press the actuator Can be self - or assisted - administration ▪ Six components to

  13. Slide 13: Envelta Competitive Advantages

    FORMULATION BENEFIT MARKET POSITION ▪ Novel enkephalin formulation ▪ Potential for comparable efficacy to mu opioid without dangerous side effects ▪ No tolerance, dependence or re ward seeking behavior in animal models ▪ MET encapsulation protects enkephalins from degradation ▪ Intranasal delivery d

  14. Slide 14: AnQlar Regulatory Pathway and Market Size

    INDICATION REGULATORY PATHWAY FDA PRE - IND GUIDANCE PHASE 1 PHASE 2 PHASE 3 NDA SUBMISSION Anti - viral barrier and Reduced Brain Viral Load INDICATION MARKET SIZE DELIVERY SYSTEM Intranasal Mucosal Anti - Viral Barrier and Reduced Brain Viral Load $ 13.16 BILLION NCE (OTC) INTRANASAL MOLECULAR ENV

  15. Slide 15: AnQlar Nanoparticle GCPQ Formulation

    AnQlar (“MMS019”) is a nanoparticle - GCPQ formulation ▪ Quaternary ammonium chitosan’s (QACs) are positively charged molecules that bind electrostatically to negatively charged coronaviruses. ▪ AnQlar (GPCQ), a chitosan derivative is highly related to QACs , and can prevent the binding of coronavir

  16. Slide 16: AnQlar Molecular Envelope Technology

    ANQLAR ҹ (MMS019) MOLECULAR ENVELOPE TECHNOLOGY (MET)IS A LIQUID NANOPARTICLE DISPERSION TECHNOLOGY & IP ▪ AnQlar ҹ ( MMS019) consists of GCPQ ( N - palmitoyl - N - monomethyl - N,N - dimethyl - N,N,N - trimethyl - 6 - O - glycolchitosan) , a low molecular weight chitosan derivative that confers ant

  17. Slide 17: AnQlar Competitive Advantages

    17 NASDAQ:VRPX ANQLAR ҹ (MMS019) Competitive Advantages FORMULATION ▪ Novel Liquid Dispersion GCPQ Nanoparticle formulation ▪ Nasal (+/ - Oral) spray for daily application ▪ Acts as a MOLECULAR MASK BENEFIT ▪ AnQlar (MMS019) is muco - adhesive and can be expected to stay at the application site at l

  18. Slide 18: Epoladerm Regulatory Pathway and Market Size

    INDICATION REGULATORY PATHWAY FDA PRE - IND GUIDANCE PHASE 1 PHASE 2 PHASE 3 NDA SUBMISSION Localized Musculoskeletal Pain Chronic Osteoarthritis (OA) Pain (OSF200) INDICATION MARKET SIZE DELIVERY SYSTEM Localized Musculoskeletal Pain $ 3.3 BILLION 505(b)(2) A NOVEL, TOPICAL ANALGESIC FORMULATION 18

  19. Slide 19: Epoladerm NSAID Metered-Dose Spray Film Overview

    EPOLADERM ҹ NSAID METERED - DOSE SPRAY FILM OVERVIEW TECHNOLOGY & IP ▪ Active drug: Diclofenac Epolamine (DHEP, diclofenac - N - (2 - hydroxyethyl) pyrrolidine) ▪ Novel topical delivery system based on proprietary spray film formulation MARKET OPPORTUNITY ▪ Treatment of localized musculoskeletal pai

  20. Slide 20: The Anatomy and Action of Epoladerm Spray Film

    THE ANATOMY AND ACTION OF EPOLADERM w SPRAY FILM METERED - DOSE VALVE administers a therapeutic dose of diclofenac in an aerosolized spray CONCENTRATED DICLOFENAC SPRAY FILM with a high - level of adhesiveness, accessibility and skin - drying PRE - FILLED DEVICE WITH DICLOFENAC SOLUTION specially fo

  21. Slide 21: Epoladerm Study and Benefits

    0.00 150.00 300.00 450.00 600.00 750.00 2 4 6 8 10 12 14 16 18 20 22 24 Mean amount of diclofenac epolamine permeated through ex vivo human skin (ng) Time (h) MS77, 1.3% w/w Flector patch Epoladerm, 1.3% w/w Epoladerm w NSAID Metered - Dose Spray Film: Skin Absorption Rate Epoladerm demonstrated com

  22. Slide 22: Epoladerm Spray Film Competitive Advantages

    22 EPOLADERM ҹ SPRAY FILM Competitive Advantages SPRAY FILM versus TOPICAL PATCHES and GELS METERED - DOSE SPRAY FILM MARKET POSITION The AAFP r eleased a new clinical guideline recommending that physicians treat acute pain from non - low back musculoskeletal injuries with topical NSAIDs as first -

  23. Slide 23: Probudur Indication, Market Size and Regulatory Pathway

    INDICATION MARKET SIZE DELIVERY SYSTEM Postoperative Pain Management $ 577 MILLION LONG - ACTING LOCAL ANESTHETICS: Liposomal Encapsulated Bupivacaine INDICATION REGULATORY PATHWAY FDA PRE - IND GUIDANCE PHASE 1 PHASE 2 PHASE 3 NDA SUBMISSION Postoperative Pain Management 505(b)(2) 23 NASDAQ:VRPX

  24. Slide 24: Probudur Long-Acting Local Anesthetic Liposomal Hydrogel

    PROBUDUR ҹ LONG - ACTING LOCAL ANESTHETIC LIPOSOMAL HYDROGEL OVERVIEW TECHNOLOGY & IP ▪ Large Multi - Vesicular Vesicle (LMVV) product delivery system, consisting of encapsulated bupivacaine in hydrogel and other “GRAS” lipids MARKET OPPORTUNITY ▪ Improved onset and longer - lasting post - operative

  25. Slide 25: Pig Wound Model: Probudur Study and Benefits

    PIG WOUND MODEL: Probudur w Superior to Free Bupivacaine and Exparel ® at 96 Hours Formulation Vehicle Probudur w 30mg/kg Probudur w 50mg/kg Free Bupivacaine 9mg/kg Exparel ® 30mg/kg ▪ Probudur ҹ demonstrated longer duration and higher peak activity compared to Exparel ® ▪ Persistent analgesia noted

  26. Slide 26: Probudur vs. Free Bupivacaine and Exparel

    PROBUDUR vs. FREE BUPIVACAINE and EXPAREL® HYDROGEL ENCAPSULATION MARKET POSITION ▪ Anticipated, post - operative pain control for up to 96 hours, nearly 24 hours longer than Exparel ® ▪ Proprietary formulation for immediate and sustained pain control ▪ Developed by researchers at Hebrew University

  27. Slide 27: Executive Leadership

    EXECUTIVE LEADERSHIP 27 NASDAQ:VRPX ▪ 25+ years of pharmaceutical experience ▪ Executive experience at EKR Therapeutics, Endo Pharmaceuticals, and Purdue Pharmaceuticals ▪ Founder of Virpax, Scilex Pharmaceuticals and Prosolus ANTHONY P. MACK, MBA Chairman & CEO ▪ 25+ years pain management, clinicia

  28. Slide 28: Independent Directors

    INDEPENDENT DIRECTORS 28 NASDAQ:VRPX ▪ Chairman, Scientific and Technology Committee; Compensation Committee ▪ 21+ years of regulatory experience within the pharmaceutical industry, including Neurogene, Axovant Sciences, Dohmen Life Science Services, and Lundbeck ERIC FLOYD, PHD ▪ Chairman, Audit Co

  29. Slide 29: Cap Table

    CAP TABLE 5,747,633 18,436 5,030,018 699,179 29 Common Outstanding Options ($7.84 WAEP) Warrants ($11.78 WAEP) Fully Diluted *Company’s Info as of August 31, 2021 NASDAQ:VRPX

  30. Slide 30: Contact

    Christopher Chipman, CPA Chief Financial Officer cchipman@virpaxpharma.com 610 - 727 - 4597 30 Investor Relations Betsy Brod Affinity Growth Advisors betsy.brod@affinitygrowth.com 212 - 661 - 2231 NASDAQ:VRPX

  31. Slide 31: Comparables

    COMPARABLES *Market Caps based on company’s closing share price as of September 8, 2021 $705 Million $1.20 Billion $24.46 Billion $2.52 Billion 31 NASDAQ:VRPX

Virpax Pharmaceuticals — IPO Roadshow (September 2021) on 6ix